entertainment -WSS

entertainment

author：entertainment 2025-09-06 02:05:07 - browse：5

A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Ebola: Gilead Sciences antiviral shows promise as new treatment

WSS

Abbott's new stent may help patients with peripheral artery disease

John Green on his newest strategy for fighting tuberculosis

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

Boston hospital trains restaurant workers on naloxone for overdoses

Steward Health Care Massachusetts hospitals face fiscal disaster

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

leisure time

entertainment

hotspot

At least 13 dead in Texas as scorching temps continue

Ripples from Flovent's discontinuation is killing children with asthma

BioMarin wins approval for gene therapy to treat hemophilia A

Lilly’s weekly insulin works as well as daily products, new studies show

Hepatitis C has a cure — but many Americans still lack access to it

How to save health care price transparency rules

DIEP, the 'gold standard' of breast reconstruction, is under threat

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

How one medical school became remarkably diverse

President Biden's budget: Here's what you might have missed

leisure time

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Boston's new lab space is opening empty

Medicare coverage of Wegovy, once blocked, now looks possible

EPA limits use of carcinogenic gas for sterilizing medical devices

RaDonda Vaught links Vanderbilt hospital issues to patient death

hotspot

hotspot

explore

focus